Anti-B7-H3 antibody and use thereof
US11891445B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 24, 2019 |
| Grant date | Feb 6, 2024 |
| Priority date | — |
| Expiry date | Apr 14, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70532
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.